Skip to content

Mirodenafil

Drug profile

Also known as: mirodenafil dihydrochloride, mvix, SK3530

Korean Food and Drug Administration (KFDA) approved

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Mirodenafil is a drug catalogued in DrugCentral. It was first approved by the Korean Food and Drug Administration (KFDA) in 2007. DrugCentral lists 1 molecular target, including PDE5A. Recorded indications include Impotence.

  • Molecular targets: PDE5A (1 listed in DrugCentral).
  • Indications: Impotence.
  • Molecular formula: C26H39N5O5S; molecular weight 533.69 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Impotence

Mechanism & targets

Molecular targets (1)

TargetGeneActionActivity
cGMP-specific 3',5'-cyclic phosphodiesterasePDE5AinhibitorIC50 9.47

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2007-07-18Korean Food and Drug Administration (KFDA)——

Chemical structure

Molecular formulaC26H39N5O5S
Molecular weight533.69 g/mol
CAS number862189-95-5
InChIKeyYIEAVVIJPFEHCX-UHFFFAOYSA-N
PubChem CID135497803
CCCOC1=CC=C(C=C1C1=NC2C(N(CC)C=C2CCC)C(=O)N1)S(=O)(=O)N1CCN(CCO)CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Mirodenafil used for?

DrugCentral lists the following indications for Mirodenafil: Impotence.

How does Mirodenafil work?

Its molecular targets in DrugCentral include PDE5A (inhibitor).

When was Mirodenafil first approved?

Mirodenafil was first approved by the Korean Food and Drug Administration (KFDA) in 2007.

What is the chemical formula of Mirodenafil?

Mirodenafil has the molecular formula C26H39N5O5S and a molecular weight of 533.69 g/mol.

Browse: all drugs starting with M · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2007-07-18
AgencyKorean Food and Drug Administration (KFDA)
Targets1
Indications1
FormulaC26H39N5O5S
DrugCentral ID5005
Interactive profile